IN2012DN02493A - - Google Patents

Download PDF

Info

Publication number: IN2012DN02493A
Authority: IN; India
Prior art keywords: present; tyrosine kinase; compounds; diseases; prevention
Prior art date: 2009-09-03

Application number

Other languages

English (en)

Inventor

Guo Xialing

Zhu Zhen

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-03

Filing date

2010-09-03

Publication date

2015-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02493(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-09-03 Application filed by Allergan Inc filed Critical Allergan Inc

2015-08-28 Publication of IN2012DN02493A publication Critical patent/IN2012DN02493A/en

Links

150000001875 compounds Chemical class 0.000 abstract 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)

IN2493DEN2012 2009-09-03 2010-09-03 IN2012DN02493A (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US23960309P	2009-09-03	2009-09-03
US30661610P	2010-02-22	2010-02-22
US35669910P	2010-06-21	2010-06-21
US36053110P	2010-07-01	2010-07-01
PCT/US2010/047800 WO2011028995A1 (en)	2009-09-03	2010-09-03	Compounds as tyrosine kinase modulators

Publications (1)

Publication Number	Publication Date
IN2012DN02493A true IN2012DN02493A (pl)	2015-08-28

Family

ID=43086186

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2493DEN2012 IN2012DN02493A (pl)	2009-09-03	2010-09-03

Country Status (19)

Country	Link
US (5)	US8809534B2 (pl)
EP (2)	EP2473513B1 (pl)
JP (3)	JP5868855B2 (pl)
KR (2)	KR20120047313A (pl)
CN (2)	CN102686577A (pl)
AU (2)	AU2010289353B2 (pl)
BR (2)	BR112012004843A2 (pl)
CA (2)	CA2772625A1 (pl)
CL (2)	CL2012000592A1 (pl)
ES (1)	ES2730086T3 (pl)
IL (2)	IL218332A0 (pl)
IN (1)	IN2012DN02493A (pl)
MX (2)	MX2012002591A (pl)
NZ (2)	NZ598781A (pl)
PH (1)	PH12014500281A1 (pl)
RU (2)	RU2012112151A (pl)
SG (2)	SG178963A1 (pl)
WO (2)	WO2011028995A1 (pl)
ZA (2)	ZA201201592B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7431710B2 (en)	2002-04-08	2008-10-07	Glaukos Corporation	Ocular implants with anchors and methods thereof
MX2011000175A (es)	2008-06-25	2011-06-27	Envivo Pharmaceuticals Inc	Compuestos heterociclicos 1,2-di-substituidos.
AU2009303602B2 (en)	2008-10-14	2012-06-14	Sunshine Lake Pharma Co., Ltd.	Compounds and methods of use
KR20110133048A (ko)	2009-03-21	2011-12-09	닝 시	아미노 에스테르 유도체, 그의 염 및 이용 방법
SI2617420T1 (sl)	2009-05-07	2016-02-29	Forum Pharmaceuticals Inc.	Fenoksimetil heterociklične spojine
US12478503B2 (en)	2009-05-18	2025-11-25	Glaukos Corporation	Implants with controlled drug delivery features and methods of using same
CA2762536C (en)	2009-05-18	2019-05-21	Dose Medical Corporation	Drug eluting ocular implant
US10206813B2 (en)	2009-05-18	2019-02-19	Dose Medical Corporation	Implants with controlled drug delivery features and methods of using same
US8906944B2 (en) *	2009-09-03	2014-12-09	Allergan, Inc.	Compounds as tyrosine kinase modulators
MX2012002591A (es)	2009-09-03	2012-04-02	Allergan Inc	Compuestos como moduladores de tirosina cinasas.
US9340555B2 (en)	2009-09-03	2016-05-17	Allergan, Inc.	Compounds as tyrosine kinase modulators
EP2654715B1 (en)	2010-11-24	2017-01-25	Dose Medical Corporation	Drug eluting ocular implant
US10245178B1 (en)	2011-06-07	2019-04-02	Glaukos Corporation	Anterior chamber drug-eluting ocular implant
RU2622034C2 (ru) *	2012-02-09	2017-06-09	Мерк Патент Гмбх	ПРОИЗВОДНЫЕ ФУРО[3,2-В]- И ТИЕНО[3,2-В]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TBK1 И IKKε
WO2015069287A1 (en) *	2013-11-08	2015-05-14	Allergan, Inc.	Compounds as tyrosine kinase modulators
US9908872B2 (en)	2013-12-13	2018-03-06	Dana-Farber Cancer Institute, Inc.	Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) *	2013-12-13	2021-06-02	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	リンパ形質細胞性リンパ腫を処置する方法
CN106866623A (zh) *	2014-04-08	2017-06-20	北大方正集团有限公司	多取代的吡啶化合物、制备方法、用途及药物组合物
US20150342875A1 (en)	2014-05-29	2015-12-03	Dose Medical Corporation	Implants with controlled drug delivery features and methods of using same
MX389591B (es)	2014-08-29	2025-03-20	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
CN104326985A (zh) *	2014-09-24	2015-02-04	安润医药科技（苏州）有限公司	利你法尼的制备方法
JP6788583B2 (ja)	2014-10-22	2020-11-25	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	増殖性疾患を処置するためのチアゾリル含有化合物
WO2017040853A1 (en)	2015-09-02	2017-03-09	Glaukos Corporation	Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en)	2015-09-25	2017-03-30	Glaukos Corporation	Punctal implants with controlled drug delivery features and methods of using same
WO2017157332A1 (zh) *	2016-03-18	2017-09-21	江苏恒瑞医药股份有限公司	芳香酰胺类衍生物、其制备方法及其在医药上的应用
JP7003110B2 (ja)	2016-04-20	2022-01-20	ドーズメディカルコーポレーション	生体吸収性眼球薬物送達デバイス
CN107663202B (zh) *	2016-07-29	2020-09-04	西华大学	3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
JP7086987B2 (ja)	2017-03-21	2022-06-20	ザスクリプスリサーチインスティテュート	銅およびニッケル触媒による脱炭酸ホウ素化反応
MY200228A (en)	2017-05-11	2023-12-15	Bristol Myers Squibb Co	Thienopyridines and benzothiophenes useful as irak4 inhibitors
CN110770210A (zh) *	2017-05-18	2020-02-07	Pi工业有限公司	新颖的脒化合物
HUE066335T2 (hu)	2018-10-05	2024-07-28	Annapurna Bio Inc	Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
EP3886854A4 (en)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4966849A (en)	1985-09-20	1990-10-30	President And Fellows Of Harvard College	CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en)	1987-12-24	1993-06-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Styryl compounds which inhibit EGF receptor protein tyrosine kinase
CA2078214C (en)	1990-04-02	1995-03-28	Robert Lee Dow	Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en)	1990-04-16	1994-04-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
AU658646B2 (en)	1991-05-10	1995-04-27	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1992021660A1 (en)	1991-05-29	1992-12-10	Pfizer, Inc.	Tricyclic polyhydroxylic tyrosine kinase inhibitors
SK283413B6 (sk)	1992-08-06	2003-07-01	Warner-Lambert Company	2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze
US5330992A (en)	1992-10-23	1994-07-19	Sterling Winthrop Inc.	1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en)	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
WO1999020617A1 (en) *	1997-10-21	1999-04-29	Active Biotech Ab	Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
ATE419239T1 (de) *	2000-10-20	2009-01-15	Eisai R&D Man Co Ltd	Verfahren zur herstellung von 4-phenoxy chinolin derivaten
JP2004528379A (ja)	2001-05-08	2004-09-16	シエーリングアクチエンゲゼルシャフト	Ｖｅｇｆｒ−２およびｖｅｇｆｒ−３インヒビターとしての選択的アントラニルアミドピリジンアミド
AU2002341881B2 (en)	2001-09-27	2008-05-08	Allergan, Inc.	3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6541504B1 (en)	2002-04-03	2003-04-01	Allergan Sales, Llc	(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
TWI319387B (en) *	2002-04-05	2010-01-11	Astrazeneca Ab	Benzamide derivatives
UA77303C2 (en) *	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US20050058689A1 (en)	2003-07-03	2005-03-17	Reactive Surfaces, Ltd.	Antifungal paints and coatings
US6747025B1 (en)	2002-11-27	2004-06-08	Allergan, Inc.	Kinase inhibitors for the treatment of disease
GB0229022D0 (en) *	2002-12-12	2003-01-15	Novartis Ag	Organic Compounds
JP4927533B2 (ja) *	2003-02-28	2012-05-09	ニッポネックスインコーポレイテッド	癌その他の疾患の治療に有用な置換ピリジン誘導体
WO2004113274A2 (en) *	2003-05-20	2004-12-29	Bayer Pharmaceuticals Corporation	Diaryl ureas with kinase inhibiting activity
BRPI0414011A (pt) *	2003-08-29	2006-10-24	Pfizer	naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
EP1660504B1 (en) *	2003-08-29	2008-10-29	Pfizer Inc.	Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005110410A2 (en) *	2004-05-14	2005-11-24	Abbott Laboratories	Kinase inhibitors as therapeutic agents
CA2589773A1 (en) *	2004-12-22	2006-06-29	Astrazeneca Ab	Pyridine carboxamide derivatives for use as anticancer agents
TWI422376B (zh) *	2005-01-25	2014-01-11	Synta Pharmaceuticals Corp	用於炎症及免疫相關用途之化合物
US8802721B2 (en) *	2005-01-25	2014-08-12	Synta Pharmaceuticals Corp.	Thiophene compounds for inflammation and immune-related uses
CA2600570C (en)	2005-03-14	2011-12-06	Transtech Pharma, Inc.	Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors
JO2787B1 (en) *	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
DK1904504T3 (da)	2005-05-20	2014-06-23	Methylgene Inc	Inhibitorer af vegf-receptor- og hgf-receptorsignalering
EP1891047A4 (en) *	2005-06-03	2008-07-09	Bayer Healthcare Ag	A 1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID SUITABLE FOR THE CHEMOTHERAPY OF CANCER
DE102005062742A1 (de) *	2005-12-22	2007-06-28	Bayer Schering Pharma Ag	Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
WO2007076474A1 (en) *	2005-12-23	2007-07-05	Kalypsys, Inc.	Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
EP1989211A2 (en) *	2006-01-30	2008-11-12	Array Biopharma, Inc.	Heterobicyclic thiophene compounds for the treatment of cancer
RU2008141761A (ru) *	2006-03-22	2010-04-27	Вертекс Фармасьютикалз Инкорпорейтед (Us)	ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
WO2007107005A1 (en) *	2006-03-22	2007-09-27	Methylgene, Inc.	Inhibitors of protein tyrosine kinase activity
US7790756B2 (en)	2006-10-11	2010-09-07	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
AU2008242720A1 (en) *	2007-04-20	2008-10-30	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CA2685529A1 (en) *	2007-04-30	2008-11-06	Abbott Laboratories	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
ES2635131T3 (es) *	2007-08-29	2017-10-02	Methylgene Inc.	Inhibidores de la actividad de la proteína tirosina cinasa
ES2593279T3 (es) *	2007-08-29	2016-12-07	Methylgene Inc.	Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados
US20090118276A1 (en)	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2009070328A1 (en)	2007-11-26	2009-06-04	The Regents Of The University Of California	Modulators of the epidermal growth factor receptor (egfr) pathway for use in the treatment or prevention of substance abuse
US20100324086A1 (en) *	2008-02-19	2010-12-23	Novasaid Ab	Compounds and methods
NZ588355A (en) *	2008-03-05	2012-03-30	Methylgene Inc	Inhibitors of protein tyrosine kinase activity
ES2435918T3 (es) *	2008-09-26	2013-12-26	National Health Research Institutes	Compuestos multicíclicos condensados como inhibidores de las proteína-cinasas
US8906944B2 (en) *	2009-09-03	2014-12-09	Allergan, Inc.	Compounds as tyrosine kinase modulators
MX2012002591A (es)	2009-09-03	2012-04-02	Allergan Inc	Compuestos como moduladores de tirosina cinasas.

2010
- 2010-09-03 MX MX2012002591A patent/MX2012002591A/es not_active Application Discontinuation
- 2010-09-03 NZ NZ598781A patent/NZ598781A/en not_active IP Right Cessation
- 2010-09-03 CN CN2010800482682A patent/CN102686577A/zh active Pending
- 2010-09-03 EP EP10752975.2A patent/EP2473513B1/en not_active Not-in-force
- 2010-09-03 SG SG2012015038A patent/SG178963A1/en unknown
- 2010-09-03 WO PCT/US2010/047800 patent/WO2011028995A1/en not_active Ceased
- 2010-09-03 EP EP10760159.3A patent/EP2473501B1/en not_active Not-in-force
- 2010-09-03 CA CA2772625A patent/CA2772625A1/en not_active Abandoned
- 2010-09-03 KR KR1020127008527A patent/KR20120047313A/ko not_active Withdrawn
- 2010-09-03 ES ES10760159T patent/ES2730086T3/es active Active
- 2010-09-03 AU AU2010289353A patent/AU2010289353B2/en not_active Ceased
- 2010-09-03 US US12/875,223 patent/US8809534B2/en active Active
- 2010-09-03 CA CA2772718A patent/CA2772718C/en active Active
- 2010-09-03 WO PCT/US2010/047816 patent/WO2011029001A1/en not_active Ceased
- 2010-09-03 RU RU2012112151/04A patent/RU2012112151A/ru not_active Application Discontinuation
- 2010-09-03 BR BR112012004843A patent/BR112012004843A2/pt not_active IP Right Cessation
- 2010-09-03 US US12/875,218 patent/US8614234B2/en active Active
- 2010-09-03 IN IN2493DEN2012 patent/IN2012DN02493A/en unknown
- 2010-09-03 MX MX2012002596A patent/MX2012002596A/es not_active Application Discontinuation
- 2010-09-03 BR BR112012004718A patent/BR112012004718A2/pt not_active IP Right Cessation
- 2010-09-03 KR KR1020127008525A patent/KR20120082890A/ko not_active Withdrawn
- 2010-09-03 RU RU2012109233/04A patent/RU2012109233A/ru not_active Application Discontinuation
- 2010-09-03 JP JP2012528084A patent/JP5868855B2/ja not_active Expired - Fee Related
- 2010-09-03 NZ NZ598455A patent/NZ598455A/en not_active IP Right Cessation
- 2010-09-03 AU AU2010289359A patent/AU2010289359A1/en not_active Abandoned
- 2010-09-03 SG SG2012015053A patent/SG178965A1/en unknown
- 2010-09-03 JP JP2012528089A patent/JP2013503903A/ja active Pending
- 2010-09-03 CN CN2010800389522A patent/CN102498114A/zh active Pending
2012
- 2012-02-27 IL IL218332A patent/IL218332A0/en unknown
- 2012-02-28 IL IL218374A patent/IL218374A0/en unknown
- 2012-03-02 CL CL2012000592A patent/CL2012000592A1/es unknown
- 2012-03-02 ZA ZA2012/01592A patent/ZA201201592B/en unknown
- 2012-03-02 CL CL2012000587A patent/CL2012000587A1/es unknown
- 2012-03-05 ZA ZA2012/01627A patent/ZA201201627B/en unknown
2013
- 2013-10-15 US US14/054,444 patent/US9328103B2/en active Active
2014
- 2014-02-03 PH PH12014500281A patent/PH12014500281A1/en unknown
2015
- 2015-07-08 US US14/793,913 patent/US9475801B2/en active Active
2016
- 2016-01-06 JP JP2016001387A patent/JP6109974B2/ja not_active Expired - Fee Related
- 2016-09-19 US US15/269,612 patent/US9725433B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ598781A (en)	2014-05-30
CL2012000592A1 (es)	2012-08-03
EP2473513A1 (en)	2012-07-11
JP6109974B2 (ja)	2017-04-05
KR20120082890A (ko)	2012-07-24
JP2013503903A (ja)	2013-02-04
RU2012109233A (ru)	2013-10-10
CN102498114A (zh)	2012-06-13
CA2772718C (en)	2018-02-20
CL2012000587A1 (es)	2012-08-24
SG178963A1 (en)	2012-04-27
IL218332A0 (en)	2012-04-30
US8614234B2 (en)	2013-12-24
KR20120047313A (ko)	2012-05-11
AU2010289353B2 (en)	2016-12-08
US20170066738A1 (en)	2017-03-09
MX2012002596A (es)	2012-07-03
US20140100212A1 (en)	2014-04-10
WO2011028995A1 (en)	2011-03-10
EP2473501A1 (en)	2012-07-11
CA2772718A1 (en)	2011-03-10
WO2011029001A1 (en)	2011-03-10
ES2730086T3 (es)	2019-11-08
RU2012112151A (ru)	2013-10-10
CA2772625A1 (en)	2011-03-10
US8809534B2 (en)	2014-08-19
EP2473501B1 (en)	2019-02-20
AU2010289353A1 (en)	2012-03-29
JP2013503901A (ja)	2013-02-04
BR112012004718A2 (pt)	2017-05-23
AU2010289359A1 (en)	2012-03-29
IL218374A0 (en)	2012-04-30
US20160090372A1 (en)	2016-03-31
ZA201201627B (en)	2012-11-28
JP2016104785A (ja)	2016-06-09
US20110053973A1 (en)	2011-03-03
ZA201201592B (en)	2012-11-28
MX2012002591A (es)	2012-04-02
CN102686577A (zh)	2012-09-19
BR112012004843A2 (pt)	2019-09-24
US9328103B2 (en)	2016-05-03
EP2473513B1 (en)	2019-06-05
PH12014500281A1 (en)	2015-09-07
US20110053905A1 (en)	2011-03-03
US9725433B2 (en)	2017-08-08
JP5868855B2 (ja)	2016-02-24
NZ598455A (en)	2014-03-28
US9475801B2 (en)	2016-10-25
SG178965A1 (en)	2012-04-27

Publication	Publication Date	Title
IN2012DN02493A (pl)	2015-08-28
TN2012000171A1 (en)	2013-12-12	Synthetic methods for spiro-oxindole compounds
EA201500175A1 (ru)	2015-05-29	Соединения и композиции в качестве ингибиторов протеинкиназ
GEP201706695B (en)	2017-07-10	Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
TN2011000673A1 (en)	2013-05-24	Bace inhibitors
MY160468A (en)	2017-03-15	Novel amino azaheterocyclic carboxamides
MY151246A (en)	2014-04-30	Benzofuranyl derivatives
MX2010009207A (es)	2011-03-03	Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2011008864A (es)	2011-09-15	Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
UA102251C2 (ru)	2013-06-25	Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201690391A1 (ru)	2016-08-31	Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
MX2009007104A (es)	2009-09-18	Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
WO2011014795A3 (en)	2011-06-03	Compounds and compositions as syk kinase inhibitors
MX2012001419A (es)	2012-03-16	Compuestos biciclicos novedosos de urea.
MX2010007490A (es)	2010-08-17	Preparacion de derivados de sulfamida.
MX336611B (es)	2016-01-22	Inhibidores selectivos de glucosidasas y sus usos.
MX2012001413A (es)	2012-03-21	Compuestos azaheterociclicos novedosos.
EA201290329A1 (ru)	2012-12-28	Селективные гетрероциклические модуляторы рецептора сфингозин-1-фосфата
MX2014012266A (es)	2014-12-05	Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos.
MX2010002899A (es)	2010-04-09	Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
MX2013002851A (es)	2013-05-28	Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
GEP20156315B (en)	2015-07-10	Oxazoline and isoxazoline derivatives as crac modulators
TN2012000469A1 (en)	2014-01-30	Use of novel pan-cdk inhibitors for treating tumors
MX2013006670A (es)	2013-07-29	Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX2011008126A (es)	2011-08-17	Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.